Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.45 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 6.90%. A quarter ago, it was expected that this company would post a loss of $0.47 per share when it actually produced a loss of $0.36, delivering a surprise of 23.40%. Over the last four quarters, the company has surpass ...

产品监管和商业化 - 公司LungFit PH系统于2022年6月获得FDA批准，用于改善氧合并减少需要体外膜肺氧合的新生儿持续性肺动脉高压[162] - 公司预计2024年下半年获得欧盟CE认证[163] - 公司认为LungFit PH在美国的潜在市场规模约为3.5亿美元,全球约为7亿美元[163] 临床试验和研发进展 - 公司于2020年底启动了使用LungFit PRO系统(150ppm浓度NO)治疗病毒性社区获得性肺炎(包括COVID-19)的临床试验[166] - 临床试验结果显示,使用高浓度NO治疗可以缩短住院时间,改善氧饱和度[167] - 临床试验数据显示,高浓度NO治疗可以有效降低C反应蛋白水平[168] - 公司已于2023年下半年在美国启动了新的临床试验,但目前暂时暂停该试验,等待未来融资[168] - 公司完成了3项支气管肺炎试点研究，数据显示间歇性吸入高浓度一氧化氮可缩短住院时间和加快出院准备[170] - 公司进行了长期安全性研究,结果显示间歇性吸入高浓度一氧化氮治疗支气管肺炎具有良好的长期安全性[171] - 公司认为目前的一氧化氮数据支持在支气管肺炎和肺炎患者中进一步开展关键性临床试验[172] - 公司在2022年5月至10月期间发布了非结核分枝杆菌肺部感染临床试验的积极中期数据和最终结果[176,177] - 公司的子公司Beyond Cancer在2021年第四季度完成3000万美元的私募融资,用于加速其高浓度一氧化氮治疗实体瘤的临床前和临床开发[178,179] - Beyond Cancer在2022年至2023年发布了多项高浓度一氧化氮治疗实体瘤的积极临床前数据,并启动了首次人体试验[180,181,183,184,185,186,187] 财务状况 - 公司在2024年6月30日季度实现收入683,000美元，同比增长1,057%[195] - 研发费用为6,009,000美元，同比增加1,314,000美元，主要由于Beyond Air和Autism项目开发成本增加[203] - 销售、一般及管理费用为7,239,000美元，同比减少3,697,000美元，主要由于股票激励费用和薪酬等下降[204] - 公司在2024年6月30日季度净亏损12,201,000美元，每股亏损0.27美元[207] - 公司在2024年6月30日季度经营活动现金流出10,180,000美元[210] - 公司在2024年6月30日季度投资活动现金流入3,114,000美元，主要由于赎回了部分投资性证券[212] - 公司在2024年6月30日季度融资活动现金流出264,000美元，主要用于偿还贷款[213] - 公司在2024年6月30日拥有现金及现金等价物21,400,000美元，其中Beyond Cancer子公司占8,200,000美元[214] - 公司与Circassia Limited达成和解协议，需支付总额10,500,000美元分三期支付[216] - 公司与Avenue Capital Management II, L.P.签订40,000,000美元贷款协议，首期17,500,000美元已于2023年6月15日提取[218] 持续经营和未来资本需求 - 公司能否持续经营至2025财年第一季度将主要取决于LungFit PH的成功商业化推广,以及在其他地区寻找合作伙伴,以及筹集额外资金以支持公司运营直至产生现金流[221] - 公司无法估计完成研发产品候选物所需的资本支出和运营费用的增加[222] - 公司未来的资本需求将取决于多个因素,包括研发进度和成本、LungFit系统商业化、临床试验规模和数量、获得监管批准的时间和成本、知识产权维护成本、生产放大成本、营销和分销成本、新适应症开发成本以及一般管理费用[223] 风险因素 - 公司面临的主要市场风险是外汇风险[224] - 贷款协议包括了常见的违约事件,一旦发生且无法在规定期限内补救,贷款代理人可能会要求加速偿还全部未偿还贷款[220]

GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. ("Beyond Cancer"), today announced the publication of its scientific article, "A safety evaluation ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Bank7 Corp. (BSVN) : This bank holding company for Bank7 has seen the Zacks Consensus Estimate for its current year earnings increasing 5.1% over the last 60 days.Okta, Inc. (OKTA) : This identity solutions company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.Silvercorp Metals Inc. (SVM) : This miner of mineral properties has seen the Zacks Consensus Estimate for its current y ...

Beyond Air, Inc. (XAIR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power ...

GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond ...

GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company") a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. ("Beyond Cancer")), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond ...

A downtrend has been apparent in Beyond Air, Inc. (XAIR) lately. While the stock has lost 7.7% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ear ...

Exhibit 99.1 Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth expected to accelerate each quarter going forward FY 2025 revenue guidance revised to greater than $10 million Implemented capital conservation strategy to reduce cash burn Conference call scheduled for 4:30 p.m. ET today, June 24 GARDEN CIT ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other jurisdiction (I.R.S. Employer of incorporation or organiz ...